Estro Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 0.15 M
- Company Age 13 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -10.84%
- Profit Growth -96.95%
- Ebitda -33.61%
- Net Worth 1.09%
- Total Assets 20.69%
About Estro Pharmaceuticals
Estro Pharmaceuticals Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 January 2012 and has a history of 13 years and one month. Its registered office is in Patna, Bihar, India.
The Corporate was formerly known as Estro Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Babloo Upadhyay, Jayendra Sinha, and Dinesh Singh serve as directors at the Company.
Company Details
- Location
Patna, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232BR2012PTC018014
- Company No.
018014
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jan 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Estro Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayendra Sinha  | Director | 10-Mar-2014 | Current |
| Babloo Upadhyay | Director | 18-Jan-2012 | Current |
| Dinesh Singh | Additional Director | 09-Aug-2023 | Current |
Financial Performance of Estro Pharmaceuticals.
Estro Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 10.84% decrease. The company also saw a substantial fall in profitability, with a 96.95% decrease in profit. The company's net worth moved up by a moderate rise of 1.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Estro Pharmaceuticals?
In 2023, Estro Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Foxglove Connect Private LimitedDinesh Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Estro Pharmaceuticals?
Estro Pharmaceuticals has a workforce of 29 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Estro Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Estro Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
